Skip to main content


Gregory K. Frykman, MD

Gregory K. Frykman, MD, is Senior Vice President, and Pharmaceutical and Biotechnology Policy Analyst formerly of the Stanford Washington Research Group in Washington, D.C.  With Mr. Glenn Gruett, Dr. Frykman co-founded Framework Therapeutics, LLC, a pharmaceutical company focusing on the development and commercialization of sodium aluminosilicate, in 2003. Dr. Frykman completed a combined fellowship in Hematology and Medical Oncology at the Johns Hopkins School of Medicine in Baltimore in 1998 and furthered his grounding in pharmaceutical product development as a recipient of the Cancer Research Training Award, National Cancer Institute (NCI) to study antineoplastics development at the joint NCI-FDA program during 1998 - 2000.  Following the training award, Dr. Frykman served as a Medical Officer in the Division of Oncology Drug Products, Center for Drug Evaluation and Research, FDA, and in late 2002 he joined the Washington Research Group, a team of policy analysts focusing on regulatory and policy issues affecting pharmaceutical and biotechnology industries. He received his medical degree in 1992 from the Loma Linda University School of Medicine and his internship and residency in Internal Medicine were both completed at the Los Angeles County – University of Southern California Medical Center in Los Angeles, California.

Dr. Frykman served most recently as a House Officer, Department of Medicine, University Specialty Hospital, has Medical Licensure in the State of California, and the State of Maryland; and is a Series 7-registered representative under the National Association of Securities Dealers.  Dr. Frykman is board certified as a Diplomate, National Board of Medical Examiners; Diplomate, American Board of Internal Medicine (1995 - 2005);  Diplomate, American Board of Hematology (1998 – 2008); and Diplomate, American Board of Medical Oncology (1999 – 2009).